An explanatory model of fatigue in women receiving adjuvant breast cancer chemotherapy

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Fatigue is the most common and disturbing complaint reported by women during adjuvant breast cancer chemotherapy, but little is known about the mechanisms influencing it. Objectives: To test an explanatory model of variables influencing fatigue in women during the first three cycles of adjuvant breast cancer chemotherapy and to determine the extent to which model variables explain fatigue at treatments and predict fatigue at cycle midpoints. Methods: A prospective, correlational design with repeated measures was used. The sample included 60 women who received chemotherapy after surgery for Stage I or II breast cancer. Fatigue was measured by the Piper Fatigue Scale. Predictor variables and measures were health and functional status (MOS SF-36), chemotherapy protocol, health-promoting lifestyle behaviors (HPLPII), nutritional status (hematocrit [Hct] and body mass index [BMI]), symptom distress (M-SDS), and initial reaction to the diagnosis of cancer (RDCQ). Multiple regression was used for path analyses. Results: Trimmed models of influences on fatigue were identified. At treatments, direct influences on fatigue were symptom distress (β = 0.45-0.76, p=0.002-0.001), chemotherapy protocol (β = 0.26, p = 0.02), and interpersonal relations (IPR) behaviors (β = -0.28, p=0.02); indirect influences were confronting reaction to the diagnosis through IPR behaviors and through symptom distress. At cycle midpoints, direct influences on fatigue were symptom distress from the previous treatment (β = 0.36-0.43, p = 0.004-0.001), physical and social function (β = -0.31-0.50, p = 0.02-0.001), and IPR behaviors (β = -22, p=0.05); an indirect influence was confronting reaction to the diagnosis (through IPR behaviors). Variance explained in fatigue ranged from 42% to 62% at treatments and from 40% to 56% at cycle midpoints. Conclusions: Further testing of the model is warranted. Findings suggest that interventions to reduce symptom distress and promote health and functional status need to be developed and evaluated for effectiveness in modifying fatigue during adjuvant breast cancer chemotherapy.

Original languageEnglish (US)
Pages (from-to)42-52
Number of pages11
JournalNursing research
Volume50
Issue number1
DOIs
StatePublished - Jan 1 2001

Fingerprint

Fatigue
Breast Neoplasms
Drug Therapy
Interpersonal Relations
Health Status
Piper
Therapeutics
Nutritional Status
Hematocrit
Life Style
Body Mass Index
Health

Keywords

  • Breast cancer chemotherapy
  • Fatigue
  • Symptom distress

ASJC Scopus subject areas

  • Nursing(all)

Cite this

An explanatory model of fatigue in women receiving adjuvant breast cancer chemotherapy. / Berger, Ann Malone.

In: Nursing research, Vol. 50, No. 1, 01.01.2001, p. 42-52.

Research output: Contribution to journalArticle

@article{c934da02c20c4fefa95674bc05182426,
title = "An explanatory model of fatigue in women receiving adjuvant breast cancer chemotherapy",
abstract = "Background: Fatigue is the most common and disturbing complaint reported by women during adjuvant breast cancer chemotherapy, but little is known about the mechanisms influencing it. Objectives: To test an explanatory model of variables influencing fatigue in women during the first three cycles of adjuvant breast cancer chemotherapy and to determine the extent to which model variables explain fatigue at treatments and predict fatigue at cycle midpoints. Methods: A prospective, correlational design with repeated measures was used. The sample included 60 women who received chemotherapy after surgery for Stage I or II breast cancer. Fatigue was measured by the Piper Fatigue Scale. Predictor variables and measures were health and functional status (MOS SF-36), chemotherapy protocol, health-promoting lifestyle behaviors (HPLPII), nutritional status (hematocrit [Hct] and body mass index [BMI]), symptom distress (M-SDS), and initial reaction to the diagnosis of cancer (RDCQ). Multiple regression was used for path analyses. Results: Trimmed models of influences on fatigue were identified. At treatments, direct influences on fatigue were symptom distress (β = 0.45-0.76, p=0.002-0.001), chemotherapy protocol (β = 0.26, p = 0.02), and interpersonal relations (IPR) behaviors (β = -0.28, p=0.02); indirect influences were confronting reaction to the diagnosis through IPR behaviors and through symptom distress. At cycle midpoints, direct influences on fatigue were symptom distress from the previous treatment (β = 0.36-0.43, p = 0.004-0.001), physical and social function (β = -0.31-0.50, p = 0.02-0.001), and IPR behaviors (β = -22, p=0.05); an indirect influence was confronting reaction to the diagnosis (through IPR behaviors). Variance explained in fatigue ranged from 42{\%} to 62{\%} at treatments and from 40{\%} to 56{\%} at cycle midpoints. Conclusions: Further testing of the model is warranted. Findings suggest that interventions to reduce symptom distress and promote health and functional status need to be developed and evaluated for effectiveness in modifying fatigue during adjuvant breast cancer chemotherapy.",
keywords = "Breast cancer chemotherapy, Fatigue, Symptom distress",
author = "Berger, {Ann Malone}",
year = "2001",
month = "1",
day = "1",
doi = "10.1097/00006199-200101000-00007",
language = "English (US)",
volume = "50",
pages = "42--52",
journal = "Nursing Research",
issn = "0029-6562",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - An explanatory model of fatigue in women receiving adjuvant breast cancer chemotherapy

AU - Berger, Ann Malone

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Background: Fatigue is the most common and disturbing complaint reported by women during adjuvant breast cancer chemotherapy, but little is known about the mechanisms influencing it. Objectives: To test an explanatory model of variables influencing fatigue in women during the first three cycles of adjuvant breast cancer chemotherapy and to determine the extent to which model variables explain fatigue at treatments and predict fatigue at cycle midpoints. Methods: A prospective, correlational design with repeated measures was used. The sample included 60 women who received chemotherapy after surgery for Stage I or II breast cancer. Fatigue was measured by the Piper Fatigue Scale. Predictor variables and measures were health and functional status (MOS SF-36), chemotherapy protocol, health-promoting lifestyle behaviors (HPLPII), nutritional status (hematocrit [Hct] and body mass index [BMI]), symptom distress (M-SDS), and initial reaction to the diagnosis of cancer (RDCQ). Multiple regression was used for path analyses. Results: Trimmed models of influences on fatigue were identified. At treatments, direct influences on fatigue were symptom distress (β = 0.45-0.76, p=0.002-0.001), chemotherapy protocol (β = 0.26, p = 0.02), and interpersonal relations (IPR) behaviors (β = -0.28, p=0.02); indirect influences were confronting reaction to the diagnosis through IPR behaviors and through symptom distress. At cycle midpoints, direct influences on fatigue were symptom distress from the previous treatment (β = 0.36-0.43, p = 0.004-0.001), physical and social function (β = -0.31-0.50, p = 0.02-0.001), and IPR behaviors (β = -22, p=0.05); an indirect influence was confronting reaction to the diagnosis (through IPR behaviors). Variance explained in fatigue ranged from 42% to 62% at treatments and from 40% to 56% at cycle midpoints. Conclusions: Further testing of the model is warranted. Findings suggest that interventions to reduce symptom distress and promote health and functional status need to be developed and evaluated for effectiveness in modifying fatigue during adjuvant breast cancer chemotherapy.

AB - Background: Fatigue is the most common and disturbing complaint reported by women during adjuvant breast cancer chemotherapy, but little is known about the mechanisms influencing it. Objectives: To test an explanatory model of variables influencing fatigue in women during the first three cycles of adjuvant breast cancer chemotherapy and to determine the extent to which model variables explain fatigue at treatments and predict fatigue at cycle midpoints. Methods: A prospective, correlational design with repeated measures was used. The sample included 60 women who received chemotherapy after surgery for Stage I or II breast cancer. Fatigue was measured by the Piper Fatigue Scale. Predictor variables and measures were health and functional status (MOS SF-36), chemotherapy protocol, health-promoting lifestyle behaviors (HPLPII), nutritional status (hematocrit [Hct] and body mass index [BMI]), symptom distress (M-SDS), and initial reaction to the diagnosis of cancer (RDCQ). Multiple regression was used for path analyses. Results: Trimmed models of influences on fatigue were identified. At treatments, direct influences on fatigue were symptom distress (β = 0.45-0.76, p=0.002-0.001), chemotherapy protocol (β = 0.26, p = 0.02), and interpersonal relations (IPR) behaviors (β = -0.28, p=0.02); indirect influences were confronting reaction to the diagnosis through IPR behaviors and through symptom distress. At cycle midpoints, direct influences on fatigue were symptom distress from the previous treatment (β = 0.36-0.43, p = 0.004-0.001), physical and social function (β = -0.31-0.50, p = 0.02-0.001), and IPR behaviors (β = -22, p=0.05); an indirect influence was confronting reaction to the diagnosis (through IPR behaviors). Variance explained in fatigue ranged from 42% to 62% at treatments and from 40% to 56% at cycle midpoints. Conclusions: Further testing of the model is warranted. Findings suggest that interventions to reduce symptom distress and promote health and functional status need to be developed and evaluated for effectiveness in modifying fatigue during adjuvant breast cancer chemotherapy.

KW - Breast cancer chemotherapy

KW - Fatigue

KW - Symptom distress

UR - http://www.scopus.com/inward/record.url?scp=3442890492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3442890492&partnerID=8YFLogxK

U2 - 10.1097/00006199-200101000-00007

DO - 10.1097/00006199-200101000-00007

M3 - Article

C2 - 19785244

AN - SCOPUS:3442890492

VL - 50

SP - 42

EP - 52

JO - Nursing Research

JF - Nursing Research

SN - 0029-6562

IS - 1

ER -